Xeris Pharmaceuticals Stock Price History
| XERS Stock | USD 3.35 0.19 5.37% |
Below is the normalized historical share price chart for Xeris Pharmaceuticals extending back to June 21, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Xeris Pharmaceuticals stands at 3.35, as last reported on the 8th of January, with the highest price reaching 3.60 and the lowest price hitting 3.31 during the day.
If you're considering investing in Xeris Stock, it is important to understand the factors that can impact its price. Xeris Pharmaceuticals appears to be moderately volatile, given 3 months investment horizon. Xeris Pharmaceuticals shows Sharpe Ratio of 0.12, which attests that the company had a 0.12% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Xeris Pharmaceuticals, which you can use to evaluate the volatility of the company. Please utilize Xeris Pharmaceuticals' Market Risk Adjusted Performance of 0.548, mean deviation of 2.11, and Downside Deviation of 2.73 to validate if our risk estimates are consistent with your expectations.
At this time, Xeris Pharmaceuticals' Common Stock Total Equity is comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to gain to about 166.2 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 203.3 M in 2025. . Price Earnings To Growth Ratio is likely to gain to 0.14 in 2025, whereas Price To Sales Ratio is likely to drop 2.16 in 2025. Xeris Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 21st of June 2018 | 200 Day MA 2.5955 | 50 Day MA 3.3144 | Beta 1.285 |
Xeris |
Sharpe Ratio = 0.1217
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XERS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.84 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.35 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Xeris Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xeris Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 3.3354 | Enterprise Value Ebitda (3.36) | Price Sales 2.8724 | Shares Float 142.5 M | Wall Street Target Price 4.7667 |
Xeris Pharmaceuticals Stock Price History Chart
There are several ways to analyze Xeris Stock price data. The simplest method is using a basic Xeris candlestick price chart, which shows Xeris Pharmaceuticals price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | December 5, 2024 | 3.73 |
| Lowest Price | October 10, 2024 | 2.78 |
Xeris Pharmaceuticals January 8, 2025 Stock Price Synopsis
Various analyses of Xeris Pharmaceuticals' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Xeris Stock. It can be used to describe the percentage change in the price of Xeris Pharmaceuticals from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Xeris Stock.| Xeris Pharmaceuticals Accumulation Distribution | 157,477 | |
| Xeris Pharmaceuticals Price Action Indicator | (0.20) | |
| Xeris Pharmaceuticals Price Daily Balance Of Power | (0.66) | |
| Xeris Pharmaceuticals Price Rate Of Daily Change | 0.95 |
Xeris Pharmaceuticals January 8, 2025 Stock Price Analysis
Xeris Stock Price History Data
The price series of Xeris Pharmaceuticals for the period between Thu, Oct 10, 2024 and Wed, Jan 8, 2025 has a statistical range of 0.95 with a coefficient of variation of 7.1. The daily prices for the period are distributed with arithmetic mean of 3.24. The median price for the last 90 days is 3.23. The company experienced 1:1 stock split on 6th of October 2021.| Open | High | Low | Close | Volume | ||
| 01/07/2025 | 3.54 | 3.60 | 3.31 | 3.35 | 1,954,884 | |
| 01/06/2025 | 3.63 | 3.67 | 3.50 | 3.54 | 1,250,463 | |
| 01/03/2025 | 3.48 | 3.61 | 3.47 | 3.61 | 1,463,176 | |
| 01/02/2025 | 3.39 | 3.55 | 3.39 | 3.46 | 1,314,600 | |
| 12/31/2024 | 3.40 | 3.48 | 3.35 | 3.39 | 963,949 | |
| 12/30/2024 | 3.40 | 3.42 | 3.27 | 3.38 | 1,010,505 | |
| 12/27/2024 | 3.49 | 3.51 | 3.38 | 3.43 | 1,360,200 | |
| 12/26/2024 | 3.47 | 3.50 | 3.42 | 3.50 | 604,200 | |
| 12/24/2024 | 3.42 | 3.52 | 3.41 | 3.47 | 520,863 | |
| 12/23/2024 | 3.47 | 3.48 | 3.32 | 3.42 | 1,542,400 | |
| 12/20/2024 | 3.35 | 3.57 | 3.35 | 3.49 | 1,522,100 | |
| 12/19/2024 | 3.30 | 3.44 | 3.27 | 3.41 | 1,535,951 | |
| 12/18/2024 | 3.43 | 3.43 | 3.17 | 3.25 | 1,875,000 | |
| 12/17/2024 | 3.38 | 3.46 | 3.35 | 3.41 | 952,052 | |
| 12/16/2024 | 3.28 | 3.46 | 3.27 | 3.37 | 1,359,500 | |
| 12/13/2024 | 3.39 | 3.46 | 3.26 | 3.28 | 2,331,623 | |
| 12/12/2024 | 3.48 | 3.63 | 3.38 | 3.40 | 1,439,030 | |
| 12/11/2024 | 3.59 | 3.59 | 3.46 | 3.51 | 1,405,336 | |
| 12/10/2024 | 3.61 | 3.74 | 3.57 | 3.58 | 1,489,644 | |
| 12/09/2024 | 3.67 | 3.75 | 3.59 | 3.61 | 966,229 | |
| 12/06/2024 | 3.71 | 3.87 | 3.67 | 3.67 | 2,095,395 | |
| 12/05/2024 | 3.57 | 3.76 | 3.54 | 3.73 | 2,760,838 | |
| 12/04/2024 | 3.42 | 3.61 | 3.40 | 3.57 | 2,044,609 | |
| 12/03/2024 | 3.32 | 3.43 | 3.30 | 3.42 | 3,623,002 | |
| 12/02/2024 | 3.29 | 3.40 | 3.29 | 3.38 | 1,211,530 | |
| 11/29/2024 | 3.47 | 3.47 | 3.28 | 3.28 | 859,612 | |
| 11/27/2024 | 3.23 | 3.52 | 3.22 | 3.45 | 2,693,409 | |
| 11/26/2024 | 3.08 | 3.20 | 3.08 | 3.18 | 1,304,553 | |
| 11/25/2024 | 3.09 | 3.14 | 3.05 | 3.08 | 782,624 | |
| 11/22/2024 | 3.04 | 3.10 | 3.02 | 3.09 | 705,974 | |
| 11/21/2024 | 3.08 | 3.12 | 3.03 | 3.04 | 1,296,505 | |
| 11/20/2024 | 2.99 | 3.08 | 2.97 | 3.06 | 1,049,869 | |
| 11/19/2024 | 2.86 | 3.01 | 2.86 | 3.01 | 783,443 | |
| 11/18/2024 | 2.91 | 2.93 | 2.82 | 2.90 | 1,406,195 | |
| 11/15/2024 | 3.07 | 3.07 | 2.91 | 2.92 | 1,899,252 | |
| 11/14/2024 | 3.15 | 3.16 | 3.04 | 3.05 | 1,256,036 | |
| 11/13/2024 | 3.20 | 3.33 | 3.15 | 3.15 | 1,849,991 | |
| 11/12/2024 | 3.25 | 3.27 | 3.03 | 3.15 | 2,883,846 | |
| 11/11/2024 | 3.41 | 3.41 | 3.21 | 3.28 | 2,424,893 | |
| 11/08/2024 | 3.40 | 3.63 | 3.06 | 3.47 | 6,683,403 | |
| 11/07/2024 | 3.34 | 3.42 | 3.29 | 3.36 | 2,568,528 | |
| 11/06/2024 | 3.32 | 3.38 | 3.25 | 3.34 | 2,339,755 | |
| 11/05/2024 | 3.25 | 3.28 | 3.10 | 3.26 | 1,463,490 | |
| 11/04/2024 | 3.20 | 3.32 | 3.13 | 3.22 | 1,186,071 | |
| 11/01/2024 | 3.26 | 3.29 | 3.17 | 3.23 | 685,346 | |
| 10/31/2024 | 3.22 | 3.29 | 3.10 | 3.22 | 1,690,366 | |
| 10/30/2024 | 3.23 | 3.31 | 3.19 | 3.23 | 1,007,262 | |
| 10/29/2024 | 3.20 | 3.25 | 3.15 | 3.23 | 951,943 | |
| 10/28/2024 | 3.25 | 3.35 | 3.21 | 3.23 | 1,323,370 | |
| 10/25/2024 | 3.25 | 3.39 | 3.20 | 3.20 | 2,168,300 | |
| 10/24/2024 | 3.10 | 3.27 | 3.08 | 3.24 | 1,845,171 | |
| 10/23/2024 | 2.99 | 3.12 | 2.96 | 3.11 | 1,230,904 | |
| 10/22/2024 | 3.00 | 3.09 | 2.98 | 3.02 | 763,671 | |
| 10/21/2024 | 3.05 | 3.09 | 2.98 | 3.03 | 1,055,016 | |
| 10/18/2024 | 3.04 | 3.12 | 3.03 | 3.06 | 936,645 | |
| 10/17/2024 | 3.04 | 3.06 | 2.97 | 3.04 | 652,637 | |
| 10/16/2024 | 3.05 | 3.11 | 3.00 | 3.04 | 1,190,143 | |
| 10/15/2024 | 2.97 | 3.05 | 2.90 | 3.02 | 1,142,481 | |
| 10/14/2024 | 2.89 | 2.99 | 2.86 | 2.97 | 747,941 | |
| 10/11/2024 | 2.78 | 2.92 | 2.78 | 2.91 | 964,785 | |
| 10/10/2024 | 2.77 | 2.79 | 2.73 | 2.78 | 948,266 |
About Xeris Pharmaceuticals Stock history
Xeris Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Xeris is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Xeris Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Xeris Pharmaceuticals stock prices may prove useful in developing a viable investing in Xeris Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 158.3 M | 166.2 M | |
| Net Loss | -85.2 M | -89.5 M |
Xeris Pharmaceuticals Quarterly Net Working Capital |
|
Xeris Pharmaceuticals Stock Technical Analysis
Xeris Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Xeris Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Xeris Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Xeris Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Xeris to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.106 | |||
| Jensen Alpha | 0.3131 | |||
| Total Risk Alpha | 0.2629 | |||
| Sortino Ratio | 0.1121 | |||
| Treynor Ratio | 0.538 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.